Published in Leuk Lymphoma on January 01, 2003
Solitary Plasmacytoma of Bone Involving Spine in a 12-year-old Boy: Report of a Rare Case and Review of Literature. J Pediatr Neurosci (2017) 0.75
High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis. N Engl J Med (2007) 5.84
Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors. J Clin Oncol (2005) 4.69
Lenalidomide and dexamethasone in transplant-ineligible patients with myeloma. N Engl J Med (2014) 2.99
Efficacy and safety of once-weekly and twice-weekly bortezomib in patients with relapsed systemic AL amyloidosis: results of a phase 1/2 study. Blood (2011) 2.82
Renal impairment in patients with multiple myeloma: a consensus statement on behalf of the International Myeloma Working Group. J Clin Oncol (2010) 2.58
Weekly and twice-weekly bortezomib in patients with systemic AL amyloidosis: results of a phase 1 dose-escalation study. Blood (2009) 2.19
Consensus recommendations for standard investigative workup: report of the International Myeloma Workshop Consensus Panel 3. Blood (2011) 2.07
Late-onset combined immune deficiency: a subset of common variable immunodeficiency with severe T cell defect. Clin Infect Dis (2009) 2.00
Update on treatment recommendations from the Fourth International Workshop on Waldenstrom's Macroglobulinemia. J Clin Oncol (2008) 1.89
Monoclonal gammopathy of renal significance: when MGUS is no longer undetermined or insignificant. Blood (2012) 1.75
Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer (2010) 1.71
A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. Cancer (2003) 1.65
Actinomycosis of the appendix and pelvis: a case report. J Reprod Med (2008) 1.58
Combined treatment with arsenic trioxide and all-trans-retinoic acid in patients with relapsed acute promyelocytic leukemia. J Clin Oncol (2003) 1.57
Update on treatment recommendations from the Third International Workshop on Waldenstrom's macroglobulinemia. Blood (2006) 1.51
Clinical, immunologic and genetic analysis of 29 patients with autosomal recessive hyper-IgM syndrome due to Activation-Induced Cytidine Deaminase deficiency. Clin Immunol (2004) 1.51
Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma (2006) 1.44
Carboplatin and paclitaxel versus cisplatin, paclitaxel and doxorubicin for first-line chemotherapy of advanced ovarian cancer: a Hellenic Cooperative Oncology Group (HeCOG) study. Eur J Cancer (2008) 1.43
High-dose therapy and autologous blood stem cell transplantation in POEMS syndrome. Blood (2002) 1.40
Lenalidomide in combination with melphalan and dexamethasone in patients with newly diagnosed AL amyloidosis: a multicenter phase 1/2 dose-escalation study. Blood (2010) 1.34
Al amyloidosis. Orphanet J Rare Dis (2012) 1.29
High dose chemotherapy in light chain or light and heavy chain deposition disease. Kidney Int (2004) 1.15
Embryonal rhabdomyosarcoma of the uterine cervix. Clin Transl Oncol (2009) 1.12
Efficacy of lenalidomide in POEMS syndrome: a retrospective study of 20 patients. Am J Hematol (2013) 1.11
Amyloid arthropathy in the course of multiple myeloma. J Rheumatol (2002) 1.08
A mixability theory for the role of sex in evolution. Proc Natl Acad Sci U S A (2008) 1.08
Prevalence of monoclonal gammopathy in patients with primary hyperparathyroidism: a prospective study. Arch Intern Med (2002) 1.08
Postoperative dose-dense sequential versus concomitant administration of epirubicin and paclitaxel in patients with node-positive breast cancer: 5-year results of the Hellenic Cooperative Oncology Group HE 10/00 phase III Trial. Breast Cancer Res Treat (2011) 1.05
Report of the Third International Workshop on Waldenstrom's macroglobulinemia. Clin Lymphoma (2005) 1.01
Prevalence of BRCA1 mutations among 403 women with triple-negative breast cancer: implications for genetic screening selection criteria: a Hellenic Cooperative Oncology Group Study. Breast Cancer Res Treat (2012) 1.01
Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev (2010) 1.00
Clinical and morphologic spectrum of renal involvement in patients with mixed cryoglobulinemia without evidence of hepatitis C virus infection. Medicine (Baltimore) (2009) 0.99
Continued survival gains in recent years among critically ill myeloma patients. Intensive Care Med (2008) 0.99
Pathogenesis and treatment of xanthomatosis associated with monoclonal gammopathy. Blood (2011) 0.99
Granulosa cell tumor of the ovary: tumor review. Integr Cancer Ther (2008) 0.96
RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. Br J Haematol (2002) 0.96
Impact of genetic abnormalities after allogeneic stem cell transplantation in multiple myeloma: a report of the Société Française de Greffe de Moelle et de Thérapie Cellulaire. Haematologica (2011) 0.93
Temozolomide with radiation therapy in high grade brain gliomas: pharmaceuticals considerations and efficacy; a review article. Molecules (2009) 0.93
Sex, mixability, and modularity. Proc Natl Acad Sci U S A (2010) 0.92
Markers of bone remodeling and skeletal morbidity in patients with solid tumors metastatic to the skeleton receiving the biphosphonate zoledronic acid. Transl Res (2010) 0.92
Treatment of Waldenstrom's macroglobulinemia with the combination of fludarabine and cyclophosphamide. Leuk Lymphoma (2003) 0.91
Endothelial vascular toxicity from chemotherapeutic agents: preclinical evidence and clinical implications. Cancer Treat Rev (2011) 0.91
All about KRAS for clinical oncology practice: gene profile, clinical implications and laboratory recommendations for somatic mutational testing in colorectal cancer. Cancer Treat Rev (2010) 0.91
Potential role of the alcohol and smoking in the squamous cell carcinoma of the head and neck: review of the current literature and new perspectives. Asian Pac J Cancer Prev (2011) 0.91
Intermittent docetaxel chemotherapy in patients with castrate-resistant prostate cancer. Urology (2011) 0.91
Immunohistochemical study of PTEN and phosphorylated mTOR proteins in familial and sporadic invasive breast carcinomas. Histopathology (2010) 0.90
Chronic urticaria and monoclonal IgM gammopathy (Schnitzler syndrome): report of 11 cases treated with pefloxacin. Arch Dermatol (2007) 0.90
Prognostic significance of phosphorylated STAT-1 expression in premenopausal and postmenopausal patients with invasive breast cancer. Histopathology (2012) 0.89
Paclitaxel and bevacizumab as first line combined treatment in patients with metastatic breast cancer: the Hellenic Cooperative Oncology Group experience with biological marker evaluation. Anticancer Res (2011) 0.89
Human herpesvirus 8 (HHV-8)-associated peritoneal primary effusion lymphoma (PEL) in two HIV-negative elderly patients. Am J Hematol (2004) 0.88
The human immunodeficiency virus-1 protease inhibitor nelfinavir impairs proteasome activity and inhibits the proliferation of multiple myeloma cells in vitro and in vivo. Haematologica (2012) 0.88
Arsenic trioxide is effective in the treatment of multiple myeloma in SCID mice. Eur J Haematol (2004) 0.88
Optimizing treatment strategies in myeloma cast nephropathy: rationale for a randomized prospective trial. Adv Chronic Kidney Dis (2012) 0.87
Outpatient treatment of low-risk neutropenic fever in cancer patients using oral moxifloxacin. Cancer (2005) 0.86
The Ets-1 transcription factor is required for Stat1-mediated T-bet expression and IgG2a class switching in mouse B cells. Blood (2012) 0.85
MELISSE, a large multicentric observational study to determine risk factors of venous thromboembolism in patients with multiple myeloma treated with immunomodulatory drugs. Thromb Haemost (2013) 0.85
Paclitaxel and carboplatin as first-line chemotherapy combined with gefitinib (IRESSA) in patients with advanced breast cancer: a phase I/II study conducted by the Hellenic Cooperative Oncology Group. Breast Cancer Res Treat (2005) 0.85
Excision Repair Cross-Complementation Group 1 Enzyme as a Molecular Determinant of Responsiveness to Platinum-Based Chemotherapy for non Small-Cell Lung Cancer. Biomark Insights (2008) 0.85
Advanced epithelial ovarian cancer in the elderly: chemotherapy tolerance and outcome. Anticancer Res (2007) 0.85
A phase II study of capecitabine plus oxaliplatin (XELOX): a new first-line option in metastatic colorectal cancer. Int J Gastrointest Cancer (2005) 0.85
Extent of damage and repair in the p53 tumor-suppressor gene after treatment of myeloma patients with high-dose melphalan and autologous blood stem-cell transplantation is individualized and may predict clinical outcome. J Clin Oncol (2005) 0.84
The clinical spectrum of IgM-related amyloidosis: a French nationwide retrospective study of 72 patients. Medicine (Baltimore) (2008) 0.84
Melphalan-induced DNA damage in vitro as a predictor for clinical outcome in multiple myeloma. Haematologica (2007) 0.84
Cyclin D1 in invasive breast carcinoma: favourable prognostic significance in unselected patients and within subgroups with an aggressive phenotype. Histopathology (2012) 0.83
Antineutrophil cytoplasmic antibodies of IgA class in neutrophilic dermatoses with emphasis on erythema elevatum diutinum. Arch Dermatol (2004) 0.83
Treatment of ovarian germ cell tumors with a 3-day bleomycin, etoposide, and cisplatin regimen: a prospective multicenter study. Gynecol Oncol (2004) 0.83
An immunohistochemical evaluation of the proteins Wnt1 and glycogen synthase kinase (GSK)-3β in invasive breast carcinomas. Histopathology (2013) 0.82
Ixabepilone administered weekly or every three weeks in HER2-negative metastatic breast cancer patients; a randomized non-comparative phase II trial. PLoS One (2013) 0.81
Prevalence of BRCA1 mutations in familial and sporadic greek ovarian cancer cases. PLoS One (2013) 0.80
Novel approaches for reducing free light chains in patients with myeloma kidney. Nat Rev Nephrol (2012) 0.80
Young age is associated with favorable characteristics but is not an independent prognostic factor in patients with epithelial ovarian cancer: a single institution experience. Oncology (2006) 0.80
Estimating the treatment effect from non-randomized studies: The example of reduced intensity conditioning allogeneic stem cell transplantation in hematological diseases. BMC Blood Disord (2012) 0.80
Proteasome inhibitor therapy for Waldenström's macroglobulinemia. Clin Lymphoma Myeloma Leuk (2013) 0.80
The key role of bisphosphonates in the supportive care of cancer patients. Anticancer Res (2014) 0.80
A phase II, randomized, multicenter study evaluating the combination of lapatinib and vinorelbine in women with ErbB2 overexpressing metastatic breast cancer. Breast Cancer Res Treat (2014) 0.80
Effect of combined treatment methods on quality of life in patients with pancreatic cancer. Am J Ther (2009) 0.79
Serum lipid profile and hepatic steatosis of adult beta-thalassaemia patients with chronic HCV infection. Eur J Gastroenterol Hepatol (2005) 0.79
Management of secondary immune deficiencies: what is the role of immunoglobulins? Curr Opin Allergy Clin Immunol (2013) 0.79
Left anterior descending coronary artery-left ventricular fistula presenting as unstable angina and syncope. Int J Cardiol (2004) 0.78
The concurrence of microalbuminuria and retinopathy with cardiovascular risk factors; reliable predictors of asymptomatic coronary artery disease in type 2 diabetes. Hormones (Athens) (2006) 0.77
Decreased Hsp90 expression in infiltrative lobular carcinoma: an immunohistochemical study. BMC Cancer (2010) 0.77
Four cycles of paclitaxel and carboplatin as adjuvant treatment in early-stage ovarian cancer: a six-year experience of the Hellenic Cooperative Oncology Group. BMC Cancer (2006) 0.77
Adjuvant dose-dense sequential chemotherapy with epirubicin, CMF, and weekly docetaxel is feasible and safe in patients with operable breast cancer. Med Oncol (2006) 0.77
Renal improvement in myeloma with plasma exchange. N Engl J Med (2011) 0.77
Primary treatment of low-grade non-Hodgkin's lymphoma with the combination of fludarabine and mitoxantrone: a phase II study of the Hellenic Cooperative Oncology Group. Leuk Lymphoma (2002) 0.77
Renal transplantation in light chain amyloidosis: coming out of the cupboard. Nephrol Dial Transplant (2011) 0.76
Treatment with granulocyte colony stimulating factor is associated with improvement in endothelial function. Growth Factors (2008) 0.76
Treatment of AL amyloidosis with high dose therapy and autologous stem cell transplantation. Leuk Lymphoma (2006) 0.75
Prevalence of anti-HAV antibodies in multitransfused patients with beta-thalassemia. World J Gastroenterol (2008) 0.75
Best therapy for primary amyloidosis, a not-yet-solved question. Blood (2004) 0.75
Smoking among high school students. Am J Drug Alcohol Abuse (2008) 0.75
Lowering of furosemide dosage after clinical stabilization in patients with congestive heart failure. Acta Cardiol (2003) 0.75
[Thalidomide and others: new treatment for myeloma]. Rev Prat (2003) 0.75
Laparoscopy in the evaluation of women with unexplained ascites: an invaluable diagnostic tool. J Minim Invasive Gynecol (2007) 0.75
Cardiac tamponade rapidly evolving toward constrictive pericarditis and shock as a first manifestation of noncardiac cancer. J Card Surg (2004) 0.75